BR9811823A - Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias - Google Patents

Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias

Info

Publication number
BR9811823A
BR9811823A BR9811823-4A BR9811823A BR9811823A BR 9811823 A BR9811823 A BR 9811823A BR 9811823 A BR9811823 A BR 9811823A BR 9811823 A BR9811823 A BR 9811823A
Authority
BR
Brazil
Prior art keywords
allergic
compositions
allergic reactions
reactions
inflammatory diseases
Prior art date
Application number
BR9811823-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Tahir Ahmed
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of BR9811823A publication Critical patent/BR9811823A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR9811823-4A 1997-08-04 1998-08-04 Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias BR9811823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/904,565 US5980865A (en) 1995-08-18 1997-08-04 Method for treating late phase allergic reactions and inflammatory diseases
PCT/US1998/016111 WO1999006025A1 (en) 1997-08-04 1998-08-04 Method and compositions for treating late phase allergic reactions and inflammatory diseases

Publications (1)

Publication Number Publication Date
BR9811823A true BR9811823A (pt) 2000-08-15

Family

ID=25419368

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811823-4A BR9811823A (pt) 1997-08-04 1998-08-04 Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias

Country Status (25)

Country Link
US (2) US5980865A (enExample)
EP (1) EP1003479B1 (enExample)
JP (1) JP2001511439A (enExample)
KR (1) KR100551773B1 (enExample)
CN (1) CN1092049C (enExample)
AR (1) AR005221A1 (enExample)
AT (1) ATE323500T1 (enExample)
AU (1) AU8684698A (enExample)
BR (1) BR9811823A (enExample)
CA (1) CA2298445C (enExample)
DE (1) DE69834256T2 (enExample)
DK (1) DK1003479T3 (enExample)
ES (1) ES2260843T3 (enExample)
HU (1) HUP0003013A3 (enExample)
IL (1) IL134230A0 (enExample)
NO (1) NO20000558L (enExample)
NZ (1) NZ502498A (enExample)
PL (1) PL191796B1 (enExample)
PT (1) PT1003479E (enExample)
RU (1) RU2209624C2 (enExample)
SK (1) SK1172000A3 (enExample)
TW (1) TW585771B (enExample)
UA (1) UA75022C2 (enExample)
WO (1) WO1999006025A1 (enExample)
ZA (1) ZA986890B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9917092D0 (en) 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
US20040230559A1 (en) * 1999-08-09 2004-11-18 Mark Newman Information processing device and information processing method
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
SE0001631D0 (sv) * 2000-05-04 2000-05-04 Sahltech Ab New use
CA2410577A1 (en) * 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury
EP1511466B2 (en) 2002-02-18 2015-02-25 Ockham Biotech Limited Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2003090763A1 (en) * 2002-04-24 2003-11-06 Medicarb Ab Composition and kit for the treatment of inflammatory bowel diseases
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
JPWO2004084918A1 (ja) * 2003-03-25 2006-06-29 積水化学工業株式会社 皮膚止痒外用組成物
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
RU2240801C1 (ru) * 2003-10-02 2004-11-27 Государственное учреждение Научно-исследовательский институт фармакологии Томского научного центра СО РАМН Средство, обладающее противоаллергическим действием
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
CN101010305B (zh) 2004-08-20 2010-08-11 曼金德公司 二酮哌嗪合成的催化反应
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
EP1791555B1 (en) * 2004-09-10 2013-03-13 Pharmaorigin ApS Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
TW200621794A (en) * 2004-10-06 2006-07-01 Akzo Nobel Nv Pulmonary administration of an antithrombotic compound
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
KR101384456B1 (ko) 2005-09-14 2014-04-10 맨카인드 코포레이션 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
US8057840B2 (en) * 2006-01-25 2011-11-15 Tate & Lyle Ingredients Americas Llc Food products comprising a slowly digestible or digestion resistant carbohydrate composition
ES2647080T3 (es) 2006-02-22 2017-12-19 Mannkind Corporation Un método para mejorar las propiedades farmacéuticas de micropartículas que comprenden dicetopiperazina y un agente activo
RU2322987C2 (ru) * 2006-05-23 2008-04-27 Ольга Александровна Субботина Средство для лечения иммунных заболеваний кожи
CN101095693B (zh) * 2006-06-29 2010-10-13 重庆华邦制药股份有限公司 治疗皮炎的复方药物
PT2164501E (pt) * 2007-05-31 2016-06-02 Paradigm Biopharmaceuticals Ltd Xilanos sulfatados para tratamento ou profilaxia de doenças respiratórias
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
DK2293833T3 (en) 2008-06-13 2016-05-23 Mannkind Corp DRY POWDER INHALER AND MEDICINAL ADMINISTRATION SYSTEM
CA2728523C (en) 2008-06-20 2020-03-10 Mannkind Corporation An interactive apparatus and method for real-time profiling of inhalation efforts
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CA2754595C (en) 2009-03-11 2017-06-27 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
MX2012006265A (es) * 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
MX2013004575A (es) * 2010-10-29 2013-05-17 Opko Health Inc Disacaridos hipersulfatados para tratar trastornos relacionados con la elastasa.
ES2625858T3 (es) 2011-04-01 2017-07-20 Mannkind Corporation Paquete de tipo blíster para cartuchos farmacéuticos
US20120322759A1 (en) * 2011-05-12 2012-12-20 Aventis Pharma Sa Semuloparin for the prevention of venous thromboembolism in cancer patients receiving chemotherapy
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HUE057140T2 (hu) 2011-12-07 2022-04-28 Allergan Inc Hatásos lipidszállítás humán könny-filmhez sóérzékeny emulziórendszer alkalmazásával
CA3098386C (en) 2012-07-12 2022-11-29 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
MX369136B (es) 2013-03-15 2019-10-30 Mannkind Corp Composiciones de dicetopiperazina microcristalina y metodos.
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
EP3191091B1 (en) 2014-09-12 2020-08-26 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
RU2697844C9 (ru) 2014-11-25 2019-10-01 Аллерган, Инк. Стабилизированные композиции для офтальмологического применения, содержащие омега-3-кислоты
TW201815394A (zh) 2016-08-16 2018-05-01 美商歐科製藥有限公司 具有改良口服生物可利用性之純七硫酸化雙醣
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN114053251A (zh) * 2020-07-29 2022-02-18 苏州融析生物科技有限公司 硫酸化多糖吸入制剂及其在防治新冠病毒相关疾病中的应用
US20220211746A1 (en) * 2021-01-07 2022-07-07 Bionovax Corp. Special heparinoid composition, with repair, prophylactic and anti-inflammatory effects, applied to the lungs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405120A (en) * 1966-01-27 1968-10-08 Green Cross Corp Low molecular chondroitin sulfate and method for manufacturing the same
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
IT1230582B (it) * 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
ATE217796T1 (de) * 1991-05-02 2002-06-15 Yeda Res & Dev Zusammensetzungen zur verhütung und/oder behandlung von pathologischen prozessen
CA2156735A1 (en) * 1993-02-22 1994-09-01 Ulrich-Christoph Von Arnim Pharmaceutical compositions for the treatment of inflammatory or immunological diseases and a method for the treatment of said diseases
FR2704861B1 (fr) * 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
SE9303612D0 (sv) * 1993-11-02 1993-11-02 Kabi Pharmacia Ab New use
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
SK1172000A3 (en) 2001-03-12
IL134230A0 (en) 2001-04-30
RU2209624C2 (ru) 2003-08-10
DK1003479T3 (da) 2006-07-31
PL191796B1 (pl) 2006-07-31
NZ502498A (en) 2002-05-31
WO1999006025A1 (en) 1999-02-11
CN1269715A (zh) 2000-10-11
TW585771B (en) 2004-05-01
DE69834256T2 (de) 2007-02-01
ZA986890B (en) 1999-01-28
US5980865A (en) 1999-11-09
PL338551A1 (en) 2000-11-06
JP2001511439A (ja) 2001-08-14
US6193957B1 (en) 2001-02-27
CA2298445A1 (en) 1999-02-11
EP1003479A4 (en) 2001-01-17
KR100551773B1 (ko) 2006-02-13
CN1092049C (zh) 2002-10-09
NO20000558L (no) 2000-03-14
NO20000558D0 (no) 2000-02-03
EP1003479B1 (en) 2006-04-19
EP1003479A1 (en) 2000-05-31
HUP0003013A2 (hu) 2001-01-29
HUP0003013A3 (en) 2001-11-28
ATE323500T1 (de) 2006-05-15
CA2298445C (en) 2007-07-17
UA75022C2 (en) 2006-03-15
KR20010022533A (ko) 2001-03-15
AR005221A1 (es) 1999-04-28
ES2260843T3 (es) 2006-11-01
AU8684698A (en) 1999-02-22
HK1030370A1 (en) 2001-05-04
PT1003479E (pt) 2006-08-31
DE69834256D1 (de) 2006-05-24

Similar Documents

Publication Publication Date Title
BR9811823A (pt) Método e composições para tratar reações alérgicas de fase tardia e doenças inflamatórias
Borle et al. Management of oral submucous fibrosis: a conservative approach
BR0008276A (pt) Combinações de formoterol e propionato de fluticasona para asma
AU2002221528B2 (en) Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis
WO2002087563A3 (en) Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
WO2001036510A3 (en) Use of poly(diallylamine) polymers
BR9607066A (pt) Método, composições e conjuntos para aumentar a biodisponibilidade oral de agentes farmacêuticos
IL133585A0 (en) Soluble prodrugs of paclitaxel
BR0108386C1 (pt) urato oxidase purificada (uricase), conjugado de uricase, composição farmacêutica para reduzir os nìveis de ácido úrico nos fluidos ou tecidos corporais, método para a purificação de uricase dotada de imunogenicidade reduzida
IL174991A0 (en) Steroidal sapogenins and their derivatives for treating alzheimer's disease
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
ATE272628T1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
JPH0223526B2 (enExample)
EP0797999A3 (en) Formulations of obesity protein
BR9808008A (pt) Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico.
JP2003089647A (ja) 関節性疾患治療剤
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
Rubin et al. Oral polymeric N-acetyl-D-glucosamine and osteoarthritis
WO2004084912A1 (ja) 神経障害処置剤
JP4362441B2 (ja) ビタミン、金属塩、およびインスリンまたは成長ホルモンを含有する治療用の組成物
JP5025045B2 (ja) 多硫酸化多糖類によるｔｉｍｐ産生の亢進
EP3980022B1 (en) Treatment of dupuytren's disease, osteoarthritis, or adhesive capsulitis with rhamnolipids.
BR0015270A (pt) Método e composições para tratamento de doenças pulmonares
GB2423927A (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
BR9811422A (pt) Processo para a inibição de hiperplasia celular de músculo liso vascular em um paciente humano ou em outro paciente animal de sangue quente necessitando de tal tratamento, uso de pelo menos um oligossacarìdeo sulfatado, e, composição farmacêutica ou veterinária para a inibição de hiperplasia celular de músculo liso vascular

Legal Events

Date Code Title Description
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11 E 10-VIII DA LPI9.279/96